Verification of multifaceted effects of konjac intake on type 2 diabetes

Verification of multifaceted effects of konjac intake on type 2 diabetes - Verification of multifaceted effects of konjac intake on type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033362

Enrollment

Registered

2021-03-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Patients take konjac and/or konjac products everyday for 12 weeks with the effort target of 100g or more per day. Nutritional guidance is carried out at every monthly outpatient visit. During the inte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with insulin unuse, HbA1c 7.0 to 10%, and BMI 22 or more.

Exclusion criteria

Exclusion criteria: 1. Patient who cannnot regulary visit h ospital 2. Patient with advanced diabetic retin opathy 3. Dialysis patient with diabetes 4. Patients with gastrointestinal disease (such as gastrectomy or Meckel diverticulum holder) in a state where ingestion of konjac is not recommended 5. Patients who have history of abdominal surgery and are at risk of bowel obstruction due to ingestion of konjac 6. Patients with severe ketosis, diabetic coma or anterior coma state 7. Patients with severe infections, before and after surgery, serious trauma 8. Patient who judged inappropriate d ue to the complications and treatment by attending doctor

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c after 12 week konnjac intake	—

Secondary

Measure	Time frame
1) Body weight, body mass index 2) Body composition / visceral fat level 3) Insulin resistance (insulin, HOMA-R) 4) The measured value of each blood test index related to glycolipid metabolism at each evaluation time point and the change amount from the value before ingesting the test food : hs-CRP, ghrelin, leptin, glucagon, GLP-1, LEAP 2, high molecular weight adiponectin, triglyceride, HDL-C, LDL-C, glucose. 5) The measured value of each blood biochemical test item other than 4) at the time of each evaluation and the change amount from the value before ingesting the test food. 6) Status of defecation 7) Quality of life	—

Measure

Time frame

1) Body weight, body mass index 2) Body composition / visceral fat level 3) Insulin resistance (insulin, HOMA-R) 4) The measured value of each blood test index related to glycolipid metabolism at each evaluation time point and the change amount from the value before ingesting the test food : hs-CRP, ghrelin, leptin, glucagon, GLP-1, LEAP 2, high molecular weight adiponectin, triglyceride, HDL-C, LDL-C, glucose. 5) The measured value of each blood biochemical test item other than 4) at the time of each evaluation and the change amount from the value before ingesting the test food. 6) Status of defecation 7) Quality of life

—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

University of Miyazaki, fuculty of medicine Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine

intron@med.miyazaki-u.ac.jp0985-85-2965

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026